Диссертация (1139499), страница 50
Текст из файла (страница 50)
SuzukiM.Acloseassociationbetweeninsulinresistanceanddehydroepiandrosterone sulfate in subjects with essential hypertension./ Suzuki M. [etal]// Endocr J. – 1999. – Vol.46. – P.521–8.543. Sveälv BG. Gender and age related differences in left ventricular function andgeometry with focus on the long axis./ Sveälv BG, Fritzon G, Andersson B.
// Eur JEcho. – 2006. – Vol.7. – P.298-307.544. Taddei S. Blood pressure through aging and menopause./ Taddei S. //Climacteric. – 2009. – Vol.12 Suppl 1. – P.36-40545. Taddei S. Effects of antihypertensive drugs on endothelial dysfunction: clinicalimplications./ Taddei S. [et al]// Drugs. – 2002. – Vol.62(2). – P.265-284546.
Takanashi M. Plasma leptin levels and body fat/ Takanashi M. [et al] // HormMetab Res. - 1996. – Vol.28. – P.751-752.547. Talbott E. Coronary heart disease risk factors in women with polycystic ovarysyndrome./ Talbott E [et al]// Arterioscler Thromb Vasc Biol. – 1995. –Vol.15. – P.821826.548. Task Force of the European Society of Cardiology and the North AmericanSociety of Pacing and Electrophysiology. Heart rate variability: standards ofmeasurement, physiological interpretation, and clinical use.// Circulation. – 1996.
–Vol.93. – P.1043– 65.307549. The DECODE study group. Prevalence of the metabolic syndrome and its relationto all-cause and cardiovascular mortality in nondiabetic European men and women.//Archive of Internal Medicine. – 2004. – Vol.164. – P.1066-76.550. The Fifth Joint Task Force of the European Society of Cardiology and OtherSocieties on Cardiovascular Disease Prevention in Clinical Practice (constituted byrepresentatives of nine societies and by invited experts).
European Guidelines oncardiovascular disease prevention in clinical practice (version 2012).// Eur Heart J. –2012. – Vol.33. – P.1635-1701.551. Thoenes M. Antihypertensive drug therapy and blood pressure control in men andwomen: an international perspective./ Thoenes M [et al]// J Hum Hypertens. – 2010. –Vol.24(5). – P.336-44.552. Thom T. Heart disease and stroke statistics – 2006 update: a report from theAmerican heart association statistics committee and stroke statistics subcommittee./Thom T [et al]// Circulation.
– 2006. – Vol.113. – P.e85-151.553. Thompson SG.Hemostatic factors and the risk of myocardial infarction orsudden death in patients with angina pectoris. European Concerted Action onThrombosis and Disabilities Angina Pectoris Study Group./ Thompson SG [et al]// NEngl J Med. – 1995. – Vol.332(10). – P.635–41.554. Tipton AJ. Female spontaneously hypertensive rats have a compensatory increasein renal regulatory T cells in response to elevations in blood pressure./ Tipton AJ, BabanB, Sullivan JC.
// Hypertension. – 2014. – Vol.64(3). – P.557-64.555. Tostes RC. Effects of estrogen on the vascular system./ Tostes RC. [et al]// Braz JMed Biol Res. – 2003. – Vol.36(9). – P.1143-58.556. Tostes RC. Endothelin, sex and hypertension./ Tostes RC. [et al]// Clin Sci(Lond). – 2008. – Vol.114. – P.85–97.557. Trayhurn P. Regulation of leptin production: a dominant role for the sympatheticnervous system?/ Trayhurn P. [et al]// Proc Nutr Soc. – 1998.
– Vol.57. – P.413-419.558. Tremollieres FA. Relative influence of age and menopause on total and regionalbody composition changes in postmenopausal women./ Tremollieres FA, Pouilles JM,Ribot CA. // Am J Obstet Gynecol. – 1996. – Vol.175(6). – P.1594-1600.308559. Tsai EC. Low serum testosterone level as predictor of increased visceral fat inJapanese-American man/ Tsai EC. [et al] // Int J Obes Relat Metab Disord.
- 2000. –Vol.24. – P.485-91.560. Umetani K. 24 Hour time domain heart rate variability and heart rate: relations toage and gender over nine decades./ Umetani K. [et al]//JACC. – 1997. –Vol.31(3). –P.593-601561. Vaccarino V. Ischaemic heart disease in women: are there sex differences inpathophysiology and risk factors? Position Paper from the Working Group on CoronaryPathophysiology and Microcirculation of the European Society of Cardiology./Vaccarino V [et al] on behalf of the Working Group on Coronary Pathophysiology andMicrocirculation//Cardiovasc Res.
– 2011. – Vol.90. – P.9-17562. Van Kesteren PJ. The effects of sex steroids on plasma levels of marker proteinsof endothelial cell functioning./ van Kesteren PJ [et al]// Thromb Haemost. – 1998. –Vol.79. – P.1029–1033.563. Vanhoutte PM. Endothelial dysfunction and vascular disease./ Vanhoutte PM [etal]// Acta Physiol. – 2009. – Vol.196. – P.193–222.564. Verdecchia P. Impact of Blood Pressure Variability on Cardiac andCerebrovascular Complications in Hypertension./ Verdecchia P [et al]// Am JHypertens. – 2007. - Vol.20. – P.154–61.565.
Verty AN. The dopamine receptor antagonist SCH 23390 attenuates feedinginduced by 9-tetrahydrocannabinol./ Verty AN, McGregor IS, Mallet PE. // Brain Res. –2004. – Vol.1020. – P.188-195.566. Virtanen R. Reduced heart rate variability in hypertension: associations withlifestyle factors and plasma renin activity./ Virtanen R [et al]// // J Hum Hypertens. 2003. – Vol.17(3).
– P.171-9.567. Vischer UM,. von Willebrand factor (vWf) as a plasma marker of endothelialactivation in diabetes: improved reliability with parallel determination of the vWfpropeptide (vWf:AgII)./ Vischer UM [et al]// Thromb Haemost.
– 1998. – Vol.80. –P.1002–7.309568. Vishram JK. Impact of age and gender on the prevalence and prognosticimportance of the metabolic syndrome and its components in Europeans. TheMORGAM Prospective Cohort Project./ Vishram JK [et al]// PLoS One. – 2014. –Vol.9(9). - P.e107294.569. Wagner OF. Polar secretion of endothelin-1 by cultured endothelial cells./Wagner OF [et al]// J Biol Chem. – 1992. – Vol.267. – P.16066-8570.
Wannamethee SG. Plasma leptin: Associations with metabolic, inflammatory andhaemostatic risk factors for cardiovascular disease./ Wannamethee SG [et al]//Atherosclerosis. – 2007. – Vol.191. – P.418–26.571. Wassertheil-Smoller S. Association between cardiovascular outcomes andantihypertensive drug treatment in older women./ Wassertheil-Smoller S// J Am MedAss.
– 2004. – Vol. 292. - № 23. – P.2849–2859.572. Wassertheil-Smoller S. Hypertension and its treatment in postmenopausalwomen: baseline data from the Women’s Health Initiative./ Wassertheil-Smoller S [etal]// Hypertension. – 2000. – Vol.36. – P.780 –789.573. Watanabe T. Influence of sex and age on serum nitrite/nitrate concentration inhealthy subjects./ Watanabe T [et al]// Clin Chim Acta. – 2000. – Vol.301(1-2).
–P.16979.574. Waxman DJ. Sex differences in the expression of hepatic drug metabolizingenzymes./ Waxman DJ, Holloway MG. // Mol Pharmacol. – 2009. – Vol.76. –P.215–228.575. Weber K.T. Myocardial fibrosis and the renin-angiotensin-aldosterone system/Weber K.T., Brilla C.G. // J Cardovasc Pharmacology. – 1992. – Vol. 20. – P.
48-54.576. Welsh P. Leptin predicts diabetes but not cardiovascular disease: Results from alarge prospective study in an elderly population./ Welsh P [et al]// Diabetes Care. –2009. – Vol.32. – P.308–10.577. Wilbert-Lampen U. Female sex hormones decrease constitutive endothelin-1release via endothelial sigma-1/cocaine receptors: an action independent of the steroidhormone receptors./ Wilbert-Lampen U [et al]// Endothelium. – 2005.
– Vol.12. –P.185–191.310578. Wilkins FC. Systemic hemodynamics and renal function during long-termpathophysiological increases in circulating endothelin./ Wilkins FC. [et al]// Am JPhysiol. – 1995. – Vol.268. – P.375-381.579. Wiviott SD. Differential expression of cardiac biomarkers by gender in patientswith unstable angina/non-ST-elevation myocardial infarction: a TACTICS-TIMI 18(Treat Angina with Aggrestat and determine Cost of Therapy with an Invasive orConservative Stategy – Thrombolysis In Myocardial Infarction 18) substudy./ WiviottSD [et al]// Circulation. – 2004. – Vol. 109.
– P. 580-6.580. Wogensen L. Transforming growth factor beta1-induced glomerulopathy isprevented by 17beta-estradiol supplementation./ Wogensen L. // Virchows Arch. –2004. – Vol.444. – P.561-66.581. Wolf G. Leptin and Renal Disease./ Wolf G. [et al]// Am J of Kid Dis. – 2002. –Vol.39(1). – P.1-11.582. Wood MJ. HRT to prevent cardiovascular disease. What studies show, how toadvise patients./ Wood MJ, Cox Jl. // Postgraduate medicine. – 2000.
– Vol.108(3). –P.59-72.583. WorldHealthOrganizationData//насайтеwww.un.org/esa/population/publications/ageing/ageing2009.htm584. Wouters MGAJ. Plasma homocysteine and menopausal status./ Wouters MGAJ[et al]// Eur J Clin Invest. – 1995. – Vol.25. – P.801–5.585. Wynne FL. Testosterone and coronary vascular tone: implications in coronaryartery disease./ Wynne FL, Khalil RA.// J Endocrinol Invest. – 2003. –Vol.26(2). –P.181–186.586. Yanagisawa M,. A novel potent vasoconstrictor peptide produced by vascularendothelial cells./ Yanagisawa M [et al]// Nature. – 1988. – Vol.332. –P.411–415.587. Yang YM. Study of androgen and atherosclerosis in old-age male/ Yang YM [etal]// J Zhejiang Univ Sci B. – 2005.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
